
Figure 1: Human CTLA-4 expression on T cells is confirmed by FACS analysis for HuGEMM CTLA-4 knock-in models.
Evaluate human specific biological therapies in vivo with humanized drug target mouse models
The HuGEMM humanized CTLA-4 mouse provides a translational model for testing your human specific anti-CTLA-4 agents. This chimeric model has humanized CTLA-4 receptors and a functional mouse immune system.
The CTLA-4 model was developed by replacing mouse exons 2 and 3 with their human counterparts, while murine exons 1 and 4 remain. This allows the in vivo efficacy evaluation of human specific therapeutic antibodies which can recognize the humanized receptor.
Figure 1: Human CTLA-4 expression on T cells is confirmed by FACS analysis for HuGEMM CTLA-4 knock-in models.
Figure 1: Human CTLA-4 expression on T cells is confirmed by FACS analysis for HuGEMM CTLA-4 knock-in models.
Figure 2: Validation of HuGEMM CTLA-4 with a Yervoy® analog. Tumor growth inhibition of MC38 tumor cells is observed following treatment with anti-hCTLA-4.
Figure 2: Validation of HuGEMM CTLA-4 with a Yervoy® analog. Tumor growth inhibition of MC38 tumor cells is observed following treatment with anti-hCTLA-4.